$80

Peptides
Zetide
Zetide (tirzepatide) research peptide, a dual GIP and GLP-1 receptor agonist. Supplied as a lyophilised powder in 30mg vials.
Supplied as lyophilised powder in a 30mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.
Product information
About Zetide
Tirzepatide (LY3298176)
Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.
Zetide is tirzepatide, a synthetic 39-amino-acid peptide that acts as a dual agonist of the GIP and GLP-1 receptors. It was developed by Eli Lilly under the code LY3298176 and carries a C20 fatty diacid side chain that binds albumin and extends its half-life.
Tirzepatide peptide is one of the most studied compounds in incretin and metabolic research. Published work covers its receptor pharmacology, its effect on insulin secretion and glucose metabolism in laboratory models, and large clinical trials in type 2 diabetes and obesity. It is frequently compared with retatrutide, a triple agonist, and with selective GLP-1 receptor agonists.
Quantified Peptides supplies Zetide (tirzepatide) 30mg as a lyophilised research peptide in a sealed vial, dispatched from Sydney, Australia. It is a reference material for in-vitro laboratory research into dual incretin receptor agonism.
- Type
- Dual GIP and GLP-1 receptor agonist
- Also Known As
- Tirzepatide, LY3298176
- Research Areas
- Incretin receptor signalling, glucose metabolism, weight research
- Length
- 39 amino acids, C20 fatty diacid
- Molecular Formula
- C225H348N48O68
- Molecular Weight
- 4813.45 g/mol
- CAS Number
- 2023788-19-2
- Primary Receptors
- GIP receptor, GLP-1 receptor
- Key Pathway
- cAMP signalling
- 01GIP Receptor AgonismTirzepatide is based on the native GIP sequence and acts as an agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor. Research examines GIP receptor signalling in pancreatic beta cells and in adipose tissue models.
- 02GLP-1 Receptor AgonismThe same molecule activates the glucagon-like peptide-1 (GLP-1) receptor. Studies describe it as an imbalanced dual agonist, with greater activity at the GIP receptor, and compare its cAMP signalling with selective GLP-1 receptor agonists.
- 03Clinical InvestigationTirzepatide has been studied in the SURPASS and SURMOUNT clinical trial programmes for glucose control and body weight. It is an approved prescription medicine in a number of countries; the material supplied here is a research compound and not that medicine.
References
- 1Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.
- 2Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
- 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=tirzepatide
Also in this range.
Compounds the supplier files alongside this one.


